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Abstract: The project highlights that the interpretation of article 30 of the TRIPS 
Agreement, developed by a panel report of the World Trade Organization (WTO) in 
Canada – Pharmaceutical Patents, is legally unsustainable, and, therefore, should be 
ignored by the Member States of the  WTO. The project posits a new interpretation to 
the terms of art. 30 of the TRIPS Agreement, which is solidly based on the case-law of 
the WTO Dispute Settlement Body (DSB). In order to prove that the TRIPS Agreement 
offers to its parties an ample policy room for the adoption of robust patent exceptions, 
the project proposes two exceptions –a so-called R&D exception and an exception for 
diagnostic tests. Both of them fully meet the requirements set by article 30 of TRIPS, 
when its terms are interpreted properly. 
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I. The Research Problem 
 
Until not long ago, the patent system only extended legal protection to inventions that 
were characterized as end-consumers products, excluding natural phenomena and pre-
existing natural resources from the list of materials eligible for protection. Therefore, 
only tangible products developed were eligible for protection; techniques of extraction 
of biochemical molecules in their natural environments were also eligible for protection, 
while the natural forces and resources as well as the technical information that 
permeates patented inventions were kept in the public domain. This was the means used 
by patent law to keep large spaces for the business sector to develop alternative 
products. This fact justified the adoption of research exceptions of limited scope, since 
the freedom to innovate was not restrained by patents. 
 
From the 1980´s, the fast and amazing scientific development of biological sciences 
urged the judicial and administrative authorities of industrialized countries and 
developing countries to reinterpret and/or amend its patent laws with the purpose of 
enabling the protection of inventions that by then were not considered eligible for 
protection. As a result, at present, many States provide protection to, inter alia, 
microorganisms, recombinant proteins, transgenic plants and animals, and sequences 
and DNA fragments including those of human origin. 
                                                                
1 The original title of the project was “The functionality of the ‘three-step test’ in widening the scope of research 
exemptions: Transposing the copyright experience into the patent field.” 
2 
 
Many of the inventions developed by the emerging sectors of the economy, notably, by 
the pharmaceutical and biotechnology industry, have special features: they can serve 
both as final products consumable by the ordinary consumer; they can also serve as 
inputs to the scientific community. Thus, it has disappeared the boundary between the 
consumer-end products and foundational developments.  
 
One of the main consequences of the granting of patents for foundational developments 
is the establishment of potential obstacles to the scientific and technological progress of 
society. This is because patents confer on their owners not just the prerogative to 
effectively control the products developed, but also the freedom of others to innovate 
through the use of patented inputs.  
 
Recalling that the technical-scientific development is a cumulative process, dependent 
on continuous access to a wealth of knowledge, the expansion of the reach of the private 
domain over foundational inventions, in the absence of robust patent exceptions, 
endangers the well being of substantial portions of humanity, especially those with 
lower purchasing power.  
 
The research exception is one of the tools most commonly adopted by the international 
community to harmonize the interests of patent holders with those of society. Even 
though its scope varies in each jurisdiction, generally, they allow third parties to carry 
out scientific experiments on the protected invention, without the prior authorization of 
the patentee. The massive presence of research exceptions in national legal systems 
reflects the understanding that the scientific and technological development should not 
be controlled by patent holders.  
 
Regardless of the peculiarities of each national law, research exceptions are designed to 
make room for society to generate new knowledge about the patented technologies and 
to allow the continuous development of new products and technologies from the 
contributions introduced by the patented objects. Specifically, research exceptions can 
promote at least three separate, but interconnected interests: enabling the scrutiny of 
patented inventions, generate new knowledge on the protected inventions and facilitate 
the development of subsequent inventions.  
 
The great difficulty now faced by scientists and industrialists worldwide is that the 
expansion of the list of patentable subject matter was accompanied by a substantial 
reduction of the scope of research exceptions or by the preservation of the old “research 
exceptions”, which were adopted in a different scientific scenario. Consequently, 
nowadays, patent rights resemble a system of absolute property that provides its holders 
the right to control all forms of use of their patented inventions. There is, therefore, a 
need to devise new patent exceptions, more adequate for the present, marked by 





Any of the 153 Member States of the World Trade Organization wishing to adopt patent 
exceptions is obliged to observe the conditions laid down by Art. 30 of the TRIPS 
Agreement which states: "Members May Provide limited exceptions to the exclusive 
rights conferred by the patent, Provided That such exceptions to not unreasonably 
conflict with normal exploitation of the patent and the not unreasonably prejudice the 
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legitimate Interests of the patent owner, taking account of the Interests of third parties 
legitimate." The terms of this provision are hard to determine: there are no tips on how 
to interpret what is a "limited exception", or what is an "unreasonable conflict" with the 
normal exploitation of patents. These ambiguities offer to WTO Member States some 
latitude to interpret them so as to enlarge the space available for the adoption of 
exceptions to patent rights, truly capable of overcoming the problems raised by the 
contemporary patent regimes. However, in the only opportunity the WTO had to 
interpret the terms of art. 30 (Canada - Pharmaceutical Patents), the Panel adopted an 
extremely conservative interpretation, directed at over-protecting the economic interests 
of patent holders. Other important interests have been neglected in the process of 
interpretation.  
 
Given this reality, the project has pursued as its main objective to study neglected 
flexibilities offered by the TRIPS Agreement to its Contracting Parties, which authorize 
the adoption of robust research exceptions. More specifically, the project  explored  the 
terms of the so-called “three-step test” in Article 30 of the TRIPS Agreement, and 
construed its terms in a manner which fosters the realization of the balance of rights 
enshrined in article 7 of the same agreement.  
 
But acknowledging that lately the large trade players – i.e. the U.S., Europe and Japan - 
have been negotiating free trade agreements with developing countries containing 
"TRIPS-plus" rules, which, as its name hints, go beyond the obligations required by the 
Agreement TRIPS, the project also aimed to investigate if these free trade agreements 
set new barriers for a more liberal interpretation of the terms of the article 30 of the 
TRIPS Agreement.  
 
All objectives set were successfully achieved. Firstly, the study identified an important 
but neglected tool of the TRIPS agreement: the obligation to interpret the terms of the 
TRIPS Agreement in accordance with the rules of treaty interpretation as laid down in 
the Vienna Convention on Law of Treaties (Articles 31 and 32). These rules, in fact, are 
not mere flexibilities offered to Member States of the WTO, because their observance is 
mandatory. However, both the Member States of the WTO as the organs that comprise 
the Dispute Settlement Body of the WTO (panels and Appellate Body) often flout these 
rules. The effect of these attacks is to restrict the space available for the establishment of 
strong exceptions to patent rights, able to promote, for instance, access to medicines and 
to proprietary knowledge.  
 
The second finding of this study was that the free trade agreements containing "TRIPS-
plus" provisions must observe the few, but important, "ceilings" set by TRIPS. These 
"ceilings" prevent the States Parties to negotiate new intellectual property  obligations 
that hurt the social and economic goals of the TRIPS Agreement and the WTO. This, in 
practice, means that WTO members may not negotiate TRIPS-plus agreements that 






To achieve the objectives outlined, the main research method used was to review the 
literature about the proper application of the rules of treaty interpretation, enshrined in 
Articles 31 and 32 of the Vienna Convention on the Law of Treaties, and to review the 
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case law of the system of disputes settlement of the WTO. These methods allowed for 
the reinterpretation of terms of art. 30 of TRIPS in an innovative manner. The new 
interpretation proposed departs from the one put forward in Canada – Pharmaceutical 
Patents, and indicates that many of the problems associated with the TRIPS Agreement 
are due to the lack of ability to interpret its terms in a correct and balanced way, and not 
to some intrinsic imbalance of the agreement. The research methods, though simple, 
were the most appropriate as they allowed the construction of a new interpretation of the 
terms of art. 30 based on the instruments that the WTO Members are obliged to use: the 
rules of interpretation of the Vienna Convention and the jurisprudence of the WTO.  
 
In principle, it was proposed to carry out interviews with research institutions in Brazil, 
to investigate the difficulties faced by the Brazilian scientific community to conduct 
scientific research in the field of life sciences. However, we had insurmountable 
difficulties: most of the researchers and institutions approached refused to grant 
interviews, and the few people who agreed to be interviewed for the project, in practice, 
proved unavailable. Anyway, the international literature on the real obstacles raised by 
contemporary patent regimes for the advancement of science and technology is wealth. 
Thus, the change in methodology has not symbolized a loss of quality of the project.  
 
 
IV. Project Activities 
 
The funds transferred by the International Development Research Centre were mainly 
used to pay the costs of salaries of the principal investigator (Edson Beas Rodrigues Jr.) 
for a period of approximately 22 months (full time), and the scholarship granted to his 
research assistant. Another part of the funds transferred have been used by the partner 
institution (McGill University) to fund the preparation of a case study on research 
exceptions in Mexico. 
 
V. Project Output 
 
The main research result of the project concluded on 30 April 3010 is a book, which 
should be published in Portuguese and in English, about art. 30 of the TRIPS 
Agreement. This book, besides explaining, in detail, the correct method of interpretation 
of the provisions of the TRIPS Agreement, also built a new interpretation to the terms 
of art. 30, and proposed two exceptions to patent rights: a Research & Development 
exception and an exception for diagnostic testing. Both exceptions proposed 
successfully pass the test of art. 30 of the TRIPS Agreement. After completion of the 
project, the principal investigator decided to make new additions in order to make it the 
most comprehensive as possible. 
 
The results of the project have not been disclosed so far, but there is an expectation that 
the work will influence the results of new litigations that may be brought before the 
WTO regarding the terms of art. 30 of the TRIPS Agreement. And most importantly, 
there is an expectation that the research output will affect developing countries and even 
industrialized countries, and persuade them to adopt exceptions to patent rights more 
appropriate to deal with the new problems raised by the contemporary patent regimes.  
 





Provisional results of the project were presented in October 2009, at IDRC headquarters 
in Ottawa for a select group, formed by IDRC staff and grantees who received funds 
under the auspices of the project "Accessing Patented Knowledge." The exchange of 
information and knowledge that took place at that time influenced the improvement of 
the project and its results. For this reason, I suggest IDRC keeps encouraging greater 
exchange of information and experience among its grantees that are carrying out 
projects on related issues. 
 
The project consumed more time than expected (22 months, and initially was expected 
to consume 18 months). Anyway, I believe the project was a success, from the 
viewpoint of the interests of developing countries: the final results indicate that there is 
a fertile field available to policy-makers from developing countries and industrialized 
countries for the enactment of new statutory exceptions to patent rights, truly robust and 
able to create a balance between the economic interests of patent holders and the 
interests of the society to substantially broaden access to knowledge for scientific and 
productive goals. This conclusion is not trivial: in general, developing countries and 
NGOs consider that the TRIPS Agreement would need to undergo substantial reforms, 
so it can be used as a tool for promoting sustainable development. This observation, 
however, is not valid in regard to space for the adoption of exceptions to patent rights. 
 
